Clinical Research Directory

Inclusion criteria include: * Age 3 months through 17 years * Weight \> 3 kg * Documented HIV infection by DNA polymerase chain reaction (PCR) or plasma RNA-PCR if \<18 months and by HIV-ELISA if 18 months and confirmed with a DNA PCR or RNA-PCR from an independent sample * Undetectable HIV-1 viral load Exclusion criteria * Confirmed or suspected TB disease (evidenced by symptoms and/or clinical exam findings and/or chest radiographic findings suggestive of TB, positive mycobacterial culture or molecular TB testing, or currently on TB treatment for active TB disease) * Likely to move from the study area during the study period * Known exposure to TB cases with known or suspected resistance to isoniazid or rifampicin in the source case * TB treatment within the past year * Prior completion of a TPT course without re-exposure to persons with infectious TB since TPT completion * Receipt of once-daily INH for \>30 days that was given for at least 14 consecutive days in the 30 days prior to enrolment. * Sensitivity or intolerance to dolutegravir, isoniazid, or rifamycins * Suspected acute hepatitis or known chronic or unstable liver disease\^; HBsAg positivity or anti-hepatitis A virus (HAV) Immunoglobulin M (IgM) antibody; any infant born to a Hepatitis C positive mother in whom in utero infection in the infant is unknown or under evaluation * alanine aminotransferase (ALT) \> 3 times the upper limit of normal (ULN) * Total bilirubin \> 2 .5 times the ULN * Absolute neutrophil count (ANC) ≤ 750 cells/mm3 * Estimated creatinine clearance \< 60 ml/min (Bedside Schwartz formula)\* * Pregnancy or breastfeeding (infant of a breastfeeding mother is allowed) * Women of childbearing potential who are unable or unwilling to use two forms of contraception\*\* * Weight for age Z score below 2 or severe clinical malnutrition * On prohibited medications e.g. dofetilide (see Appendix 1) * Known porphyria